Immunicy-1: Targeting BCMA with CYAD-211 to establish proof of concept of an shRNA-based allogeneic CAR T cell therapy platform

This article has no abstract
Epistemonikos ID: d3f70301599370ee32b49ae4237153bfa6495d71
First added on: Feb 13, 2025